Takeda makes an M&A move in Turkey

Eric Palmer

's CEO-in-waiting, Christophe Weber, has included emerging markets, along with oncology and gastrointestinal medicines, as one of three areas of focus. He recently said he is ready to do some deals to capitalize on those areas, and now he has executed one that straddles two of those favorites.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS